Psoriasis accounted for a 17.2% share of the global clinical trials within the Immunology therapy area in 2021, registering an increase of 1.7% when compared with the last ten-year average of 15.5% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Psoriasis
Industry sponsored trials held a 70.4% share of all the clinical trials for Psoriasis indication in 2021, registering a decrease of 0.5% when compared with the ten-year average of 70.9%. Non-industry sponsored trials accounted for a 29.6% share in 2021, registering an increase of 0.5% over the ten-year average of 29.1%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Psoriasis trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Psoriasis trials, accounting for a 58.0% share in 2021, when compared with the five-year average of 40.1% and ten-year average of 34.0%.
North America was at the second position with a 32.8% share in 2021, over the five-year average of 44.4% and ten-year average of 48.3%, followed by Europe with a 30.3% share in 2021, as against five-year and ten-year averages of 44.4% and 45.9% respectively.
Middle East and Africa stood fourth with a 4.2% share in 2021, compared with the five-year average of 5.0% and ten-year average of 5.7%, followed by South and Central America with a 4.2% share in 2021, over five-year and ten-year averages of 4.9% and 5.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Psoriasis trials, accounting for a 32.8% share in 2021, as against the five-year average of 14.2% and ten-year average of 7.8%.
The US held a 31.9% share in 2021, over the five-year average of 41.1% and ten-year average of 44.4%, followed by Poland with a 15.1% share in 2021, compared with the five-year and ten-year averages of 14.8% and 13.8% respectively.
Canada held an 11.8% share in 2021, as against the five-year average of 18.4% and ten-year average of 19.6%.
Germany held an 11.8% share in 2021, over the five-year and ten-year averages of 22.9% and 24.9% respectively.
Top regions of non-industry sponsored Psoriasis trials
Asia-Pacific was the top region for non-industry sponsored Psoriasis trials, accounting for a 58.5% share in 2021 when compared with the five-year average of 53.8% and ten-year average of 50.0%.
Middle East and Africa was at the second position with a 15.1% share in 2021, over the five-year and ten-year averages of 12.2% and 11.5% respectively, followed by North America with a 13.2% share in 2021, as against the five-year average of 12.9% and ten-year average of 16.0%.
Europe stood at the fourth position with an 11.3% share in 2021, compared with the five-year average of 21.1% and ten-year average of 21.5%, followed by South and Central America with a 1.9% share in 2021, over the five-year and ten-year averages of 0.0% and 1.0% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Psoriasis trials, accounting for a 45.3% share in 2021, as against the five-year average of 23.7% and ten-year average of 20.6%.
The US held a 13.2% share in 2021, over the five-year average of 12.9% and ten-year average of 15.7%, followed by Iran with a 9.4% share, compared with the five-year and ten-year averages of 11.0% and 9.6% respectively.
Thailand held a 5.7% share in 2021, as against the five-year average of 3.3% and ten-year average of 1.9%.
India held a 5.7% share in 2021, over the five-year average of 22.0% and ten-year average of 16.2%.
Phase I trials lead industry sponsored clinical trials for Psoriasis in 2021
Phase I trials held a 45.9% share of industry sponsored clinical trials for Psoriasis in 2021, over the five-year average of 39.0% and ten-year average of 36.7%.
Phase II trials held a 20.3% share in 2021, as against the five-year average of 22.2% and ten-year average of 23.4%. Phase III trials held a 20.3% share in 2021, compared with the five-year and ten-year averages of 23.1% and 26.2% respectively.
Phase IV trials held a 13.5% share in 2021, over the five-year average of 15.7% and ten-year average of 13.8%.
Phase II trials lead non-industry sponsored clinical trials for Psoriasis in 2021
Phase II trials held a 37.5% share of non-industry sponsored clinical trials for Psoriasis in 2021, over the five-year average of 40.9% and ten-year average of 41.5%.
Phase IV trials held a 35.7% share in 2021, as against the five-year average of 35.2% and ten-year average of 37.7%. Phase I trials held a 16.1% share, compared with the five-year and ten-year averages of 9.2% and 7.6% respectively.
Phase III trials held a 10.7% share in 2021, over the five-year average of 14.7% and ten-year average of 13.2%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
